Treatment of cancer with thymidine in combination with temozolamide
AssigneeWisconsin Alumni Research Foundation
InventorH. Ian Robins
Life of this patent
Estimating the term…
Abstract
Methods for treating cancer are provided that involve administration of a combination of the chemotherapeutic drug, temozolamide, and thymidine.
Claims4
A method for reducing myelosuppression associated with temozolomide administration in a patient comprising administering to a patient an effective dose of temozolomide in combination with thymidine wherein said thymidine inhibits poly (ADP-ribose) polymerase activity producing a synergistic cytotoxic interaction between the thymidine and the temozolomide so that a greater than additive effect of temozolomide and thymidine is realized.
A method for reducing the dose-limiting toxicity of temozolomide comprising administering to a patient an effective amount of temozolomide in combination with thymidine wherein said thymidine inhibits poly (ADP-ribose) polymerase activity producing a synergistic cytotoxic interaction between the thymidine and the temozolomide so that a greater than additive effect of temozolomide and thymidine is realized.
A method for increasing the efficacy of temozolomide in the treatment of cancer comprising administering to a patient an effective amount of temozolomide in combination with thymidine wherein said thymidine inhibits poly (ADP-ribose) polymerase activity producing a synergistic cytotoxic interaction between the thymidine and the temozolomide so that a greater than additive effect of temozolomide and thymidine is realized and wherein the cancer is sensitive to the combination of thymidine and temozolomide.
Dependencies are inferred from the claim text.